Post transplantation cyclophosphamide to prevent graft-versus-host-disease in allogeneic peripheral blood hematopoietic stem cell transplantation from HLA-matched donors / Mohamed Tarek Hamed Shouman ; Supervised Hossam Mohamed Kamel , Osman Mohamed Mansour , Mosaad Mahmoud Elgammal

By:

Mohamed Tarek Hamed Shouman

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Mohamed Tarek Hamed Shouman , 2020Description: 154 P. ; 25cmOther title:

السيكلوفوسفاميد ما بعد الزرع لمنع الطرد العكسى خلال زرع النخاع العظمى عن طريق الخلايا الجذعيه الطرفيه من متبرع متطابق كليا فى الانسجه [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (Ph.D.) - Cairo University - National cancer institute - Department of Oncology (Medical) Summary: Background: GVHD prophylaxis with Calcineurin inhibitor (CNI) and methotrexate (MTX) has been considered the standard of care. Trial initially evaluating Post-transplant Cyclophosphamide (PT-Cy) with or without immunosuppressive agents (IS) in Haploidentical donors have shown promising results. While, its use in HLA-matched donors and comparing it to conventional prophylaxis is less explored. Objective: The aim of this study is to identify the impact of post transplantation cyclophosphamide in HLA matched sibling donors receiving PBSCT on the rates of GVHD, OS, NRM, DFS and relapse compared to conventional prophylaxis. Patients and methods: 150 patients having malignant hematological disorders undergoing PBSCT with matched sibling donors (MSD) receiving different GVHD prophylaxis to compare the incidence of chronic GVHD. Group A included 75 who were studied prospectively receiving post-transplantation Cyclophosphamide as a GVHD prophylaxis given at a dose of 50 mg/kg/day on days 3 and 4 post-transplantation, and cyclosporine (CSA) starting day 5. Patients were treated at 2 transplant centers during the period from December 2017 to June 2019. Pre-transplant conditioning regimen was fludarabine and busulfan (FLU/BU) given to all of the patients. Group B included 75 closely matched patients in which there data were retrospectively collected from the same transplant center. Patients received conventional GVHD prophylaxis with CNI and methotrexate (15 mg/m2 IV day +1, 10 mg/m2 day +3,+6, +11) during the period from September 2015 to August 2019. Pre-transplant conditioning regimens were Bu/Cy (64 %), Flu/Bu (24%) and TBI/Cy (12 %)

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2020.Mo.P (Browse shelf(Opens below))		Not for loan		01010110083242000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2020.Mo.P (Browse shelf(Opens below))	83242.CD	Not for loan		01020110083242000

Thesis (Ph.D.) - Cairo University - National cancer institute - Department of Oncology (Medical)

Background: GVHD prophylaxis with Calcineurin inhibitor (CNI) and methotrexate (MTX) has been considered the standard of care. Trial initially evaluating Post-transplant Cyclophosphamide (PT-Cy) with or without immunosuppressive agents (IS) in Haploidentical donors have shown promising results. While, its use in HLA-matched donors and comparing it to conventional prophylaxis is less explored. Objective: The aim of this study is to identify the impact of post transplantation cyclophosphamide in HLA matched sibling donors receiving PBSCT on the rates of GVHD, OS, NRM, DFS and relapse compared to conventional prophylaxis. Patients and methods: 150 patients having malignant hematological disorders undergoing PBSCT with matched sibling donors (MSD) receiving different GVHD prophylaxis to compare the incidence of chronic GVHD. Group A included 75 who were studied prospectively receiving post-transplantation Cyclophosphamide as a GVHD prophylaxis given at a dose of 50 mg/kg/day on days 3 and 4 post-transplantation, and cyclosporine (CSA) starting day 5. Patients were treated at 2 transplant centers during the period from December 2017 to June 2019. Pre-transplant conditioning regimen was fludarabine and busulfan (FLU/BU) given to all of the patients. Group B included 75 closely matched patients in which there data were retrospectively collected from the same transplant center. Patients received conventional GVHD prophylaxis with CNI and methotrexate (15 mg/m2 IV day +1, 10 mg/m2 day +3,+6, +11) during the period from September 2015 to August 2019. Pre-transplant conditioning regimens were Bu/Cy (64 %), Flu/Bu (24%) and TBI/Cy (12 %)

Issued also as CD

There are no comments on this title.

to post a comment.